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INTRODUCTION

146
RESULTS
147
Examination of an intronic deletion in CNTNAP2 in an extended family with bipolar disorder 148 CNV microarray analysis was performed in two affected individuals from an extended family 149 which included five relatives affected with bipolar I disorder. A drop in signal intensity for 340 150 consecutive probes was compatible with a deletion of 131 kb in intron 1 of CNTNAP2 151 (hg19/chr7:146203548-146334635; Fig 1A) . The deletion encompasses the described binding 152 site for the transcription factor FOXP2 (hg19/chr7:146215016-146215040) [12] . The deletion 153 was detected in one of the two affected individuals examined. To infer deletion segregation 154 amongst relatives, WES-derived genotypes were used to create haplotypes across chromosome 155 7q35 ( Fig 1B) . The WES-derived haplotype analysis was uninformative due to incomplete 156 genotype data (unaffected descendants of deceased patient 8404 not included in the WES 157 study) and a likely recombination at 7q35 in the family. Thus experimental validation (in 158 patient 8401) and CNV genotyping via quantitative PCR (qPCR) was performed in all 159 individuals with DNA available from this family to assess the presence of the CNTNAP2 160 intronic deletion. The deletion was validated in subject 8401, and was also detected in one 161 unaffected descendant of deceased patient 8404 ( Fig 1C) , implying that this CNV would have 162 been present in affected subject 8404, had DNA been available. The structural variant did not 163 segregate with disease status in this family, and is unlikely to be a highly penetrant variant as 164 it was observed also in an unaffected relative ( Fig 1B) . 165 166 Structural variants affecting CNTNAP2 amongst psychiatric phenotypes 167 Several deletions and duplications have been described in neuropsychiatric phenotypes thus 168 far. In Fig 2, we present a comprehensive representation of all previously reported structural 169 variants found in CNTNAP2 in psychiatric disorders such as ASD or ID [13, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] , 170 schizophrenia or bipolar disorder (including the 131kb deletion found in the present study) [51] [52] [53] [54] , ADHD [55] , neurologic disorders such as epilepsy, Tourette syndrome or Charcot- Tooth [56] [57] [58] [59] [60] ; and finally language-related phenotypes such as speech delay, childhood 173 apraxia of speech and dyslexia [62] [63] [64] [65] . Interestingly, the structural variants reported so far 174 frequently map in intron 1, overlapping with the 131kb deletion found in our extended family, 175 and extend in some cases up to exon 4. The distribution of those structural variants across 176 different phenotypes does not vary with those found in control populations from the database 177 of genomic variants (http://dgv.tcag.ca/dgv/app/home) (Fig 2) , suggesting that structural 178 variants in CNTNAP2 are not rare events associated exclusively to disease but are present with 179 rare frequency in the general population. between CNTNAP2 and the language-associated transcription factor FOXP2 prompted many 185 studies to focus on language traits in autism or speech-related phenotypes [12-15, 23-28, 46-186 48, 50], but later, additional associations were also reported in other psychiatric phenotypes 187 [41] [42] [43] [44] [45] 49] . In Table 1 , we summarise all markers found significantly associated in these 188 previous studies, and report the corresponding P-value from the Psychiatric Genomics 189 Consortium GWAS for seven major psychiatric disorders: ADHD, anorexia nervosa, ASD, 190 bipolar disorder, MDD, OCD and schizophrenia. Nominal associations were found with ASD 191 for the following markers: rs802524 (P=0.016), rs802568 (P=0.008), rs17170073 (P=0.008), 192 and rs2710102 (which is highly correlated with 4 SNPs: rs759178, rs1922892, rs2538991, 193 rs2538976) (P=0.036); with schizophrenia for rs1859547 (P=0.044); with ADHD for 194 rs1718101 (P=0.038); in MDD for rs12670868 (P=0.047), rs17236239 (P=0.006), rs4431523 195 (P=0.001); and with anorexia nervosa for rs700273 (P=0.013). The nominal association at 196 rs1770073 and rs2710102 in ASD represents the only case in which the phenotype matches 197 between the original report and the PGC dataset. The two SNPs rs7794745 and rs2710102, 198 which were repeatedly reported as being associated and proposed to be functional SNPs, were 199 not strongly associated with any phenotype (the most significant signal being P=0.036 for 200 rs2710102 in autism). None of those associations survived corrections for multiple 201 comparisons ( Table 1) . in the latest autism GWAS (PGC2) but was present in the previous data set which included 237 5,305 ASD cases and 5,305 controls.
Next, we explored the contribution of common variants across CNTNAP2 by 239 performing a gene-based association study in European populations using GWAS summary 240 statistics from PGC data of seven psychiatric disorders (Table 2) . The only SNP predicted to be functional and which was previously reported as being associated 272 with autism was rs34712024 ( The number (N) of families in each dataset examined is given. The full list of de novo variants 291 observed is listed in S2 Table. Abbreviations: ASD, autism spectrum disorder; SCZ, 292 schizophrenia; EE, epilepsy; ID, intellectual disability; DD, developmental disability.
294
Finally, we explored the potential impact of pathogenic ultra-rare variants (URV) in 295 CNTNAP2 using available sequencing datasets of 4,483 patients with ASD and 6,135 patients 296 with schizophrenia compared with 13,042 controls. We considered only those variants 297 predicted to be pathogenic in both SIFT and Polyphen and which are ultra-rare (MAF<0.0001 298 in Non-Finnish European population). No difference in the total number of URV was observed 299 between ASD and controls (P=0.11), or between schizophrenia patients and controls (P=0.78) 300 (Table 5) . During the last decade, the CNTNAP2 gene has received considerable attention in the 308 psychiatric genetics field, with a large body of studies examining gene dosage, common or rare 309 variants across multiple major psychiatric disorders, which together provided compelling 310 evidence that CNTNAP2 may be a risk gene with pleiotropic effects in psychiatry. While 311 homozygous mutations in this gene lead to a rare and severe condition described as CASPR2 312 deficiency disorder (CDD) [7] , characterized by profound intellectual disability, epilepsy, 313 language impairment or regression [7, 8] , heterozygous mutations or common variants have 314 been suggested to be implicated in autism, whose features overlap with some observed in CDD.
315
CNTNAP2 is categorised in the SFARI database (https://gene.sfari.org) as a strong candidate 316 gene for ASD (category 2.1). Heterozygous deletions encompassing the CNTNAP2 gene were 317 described not only in autism but also in a wide range of phenotypes, including psychiatric or 318 neurologic disorders, and language-related deficiencies. These structural variants were 319 generally described as causative or highly penetrant [13, 29, 31, 55, 57, 59] .
320
Here, we describe a new deletion in a bipolar disorder patient encompassing intron 1 of 321 CNTNAP2, which overlaps with structural variants described in a number of other psychiatric 322 patients. This heterozygous deletion, which removes the FOXP2 transcription factor binding 323 site, was found in an individual with bipolar I disorder from an extended family with five 324 affected members. This deletion was observed in only two of the affected relatives and was 325 absent from two affected relatives, but was also observed in one unaffected relative who 326 underwent diagnostic interview at age >40 and therefore beyond the typical age of symptom 327 onset. Hence, the deletion was not segregating with the disease and is unlikely to represent a 328 highly penetrant risk variant in this family. Examination of the distribution of all structural 329 variants described thus far in psychiatric or neurologic patients showed comparable mapping 330 with those found in the general population, suggesting that structural variants affecting 331 CNTNAP2 may be less relevant in disease susceptibility than previously considered. Eleven
332
CNVs are described in the general population against sixteen expected (z=0.43) in ExAC 333 database (http://exac.broadinstitute.org), and the haploinsufficiency score (0.59) is relatively 334 moderate [68], suggesting that CNTNAP2 has a moderate tendency to be intolerant to structural 335 variants. However, a case-control CNV analysis is needed in psychiatric disorders, but would CNVs. All heterozygous family members carrying deletions or truncating mutations were 340 described as phenotypically healthy, suggesting a lack of correlation between these deletions 341 and any major psychiatric condition. Furthermore, parents who were carriers for heterozygous 342 deletions in psychiatric/neurologic patients were described as unaffected at the time of 343 reporting [13, 29, 31, 37, 54, 62] , with the exception of one father of a proband with neonatal 344 convulsion or another father of an epileptic patient reported as affected [56, 59] . Moreover, 345 discordant segregation for deletions in CNTNAP2 was also observed in an ASD sib-pair [13] .
346
Several psychiatric patients who were reported to carry heterozygous structural variants in 347 CNTNAP2 were also described with translocations or other chromosomal abnormalities [29, 348 30, 33, 34, 56, 58, 62-65] , therefore it is possible that these aberrations may explain the 349 phenotype independently from the observed CNVs in CNTNAP2. GABAergic interneurons [2, 4] . Controversially, ASD is not a core feature in the most recent 355 patient series reported with CASPR2 deficiency disorder [7, 8] . The association previously proposed around the relationship between heterozygous deletions in CNTNAP2 and ASD does 357 not have a support from mouse models, as heterozygous mice did not show any behavioural or 358 neuropathological abnormalities that were observed in homozygous knockouts [2] . 359 Notwithstanding this, it is possible that the combination of heterozygous CNTNAP2 deletions 360 in a genomic background of increased risk (through inheritance of other common and rare risk 361 variants at other loci) may lead to psychiatric, behavioural or neuropathological abnormalities.
362
Common variants in CNTNAP2 are another class of genetic variation associated with 363 several psychiatric or language-related phenotypes. The most interesting finding from these 364 studies converge on markers rs7794745 and rs2710102, originally reported in ASD [13, 14] , 365 and replicated later in ASD or implicated in other phenotypes [12, 15, 23, 24, [46] [47] [48] .
366
Neuroimaging studies have supported the notion that these common variants play a role in 367 psychiatric disorders. SNP rs2710102 has been implicated in brain connectivity in healthy 368 individuals [16, 18, 19] , and rs7794745 was implicated in audio-visual speech perception [69], 369 voice-specific brain function [22] , and was associated with reduced grey matter volume in left 370 superior occipital gyrus [20, 21] . These studies focused principally on language tasks in general 371 population, given the reported suggestive implications of CNTNAP2 in language impairment 372 traits of ASD or language-related phenotypes. However, the direct role of CNTNAP2 in 373 language is still unclear; indeed the language regression observed in patients with CASPR2 the small size effects of common variants [72] , which we attempted here using the largest case-control cohorts currently publicly available (PGC datasets). We did not find evidence for 382 significant association of previous reported common variants, nor did we find functional SNPs 383 with a role across disorders, or observe a combined effect for common variants of CNTNAP2 384 in the susceptibility of psychiatric disorders.
385
Rare variants of CNTNAP2 both in the promoter or coding region were also reported to 386 play a role in the pathophysiology of ASD [25, 33] . A recent study including a large number 387 of cases and controls did not find association of rare variants of CNTNAP2 in ASD [73] . Here 388 we report the largest sample investigated thus far in ASD and schizophrenia for rare variants 389 in CNTNAP2, which suggest that rare variants from this gene do not play a major role in these 390 two psychiatric disorders. Furthermore, the identification of de novo variants in CNTNAP2 in 391 combined psychiatric sequencing projects of over 15,500 trios suggest that de novo variants in 392 this gene do not increase risk for psychiatric disorders.
393
While functional studies show a relationship between certain deletions or rare variants 394 of CNTNAP2 with neuronal phenotypes relevant to psychiatric illness [25, 54, 74] , we show 395 that the genetic link between these variants and psychiatric phenotypes is tenuous. However, 396 this does not dispel the evidence that the CNTNAP2 gene, or specific genetic variations within 397 this gene, may have a real impact on neuronal functions or brain connectivity.
398
Nowadays we are able to combine large datasets to ascertain the real impact of 399 candidate genes described in the past in psychiatric disorders. Here we performed analyses 400 using large publically available datasets investigating a range of mutational mechanisms which 401 impact variability of CNTNAP2 across several psychiatric disorders. In conclusion, our results 402 converge to show a limited or likely neutral role of CNTNAP2 in the susceptibility of 403 psychiatric disorders. ASD-ID (33) ASD (13, (34) (35) (36) (37) (38) SCZ (51, 52) EP (56) (57) (58) (59) BD (PS, (52) (53) (54) SS (62) (63) (64) (65) ADHD (55) CMT2 ( 
